Dr. Sherif Hafez, Professor of Internal Medicine and Diabetes at the Faculty of Medicine, Kasr Al-Aini, said that the drug is an important breakthrough in the field of diabetes drugs in Egypt, and it reduces blood sugar levels through the kidneys and not the pancreas.
Hafez explained that this medicine combines two substances, “Empagliflozin” and “Metformin”, which are of importance for diabetics, as its availability helps reduce the number of tablets and drugs that he receives, with the same effect, which reduces the cost of treatment, and gives the highest possible health efficiency.
He revealed that 75% of the causes of death for diabetics are due to arterial defect, blood vessels and heart disease, so it is imperative to choose the most appropriate medicine for each patient.
He stressed that international research has proven that this medicine protects the heart, reduces the incidence of heart disease, and reduces the patient’s hospitalization due to heart attacks.
Dr. Hossam Kandil, Professor of Cardiology at the Faculty of Medicine, Kasr Al-Aini, said that the number of diabetics is constantly increasing, and that the Arab region has one of the highest rates in the world in the incidence of type 2 diabetes, and the incidence of it in some countries of the region reaches 25% of Population is above
He stressed that the relationship between diabetes and the heart is reciprocal, and that diabetics often develop heart disease, because diabetes causes damage to arteries, including the arteries of the heart, and said: “Diabetes is the first enemy of the heart.
The heart professor explained that recent years have witnessed a great development of diabetes treatments, after they have undergone numerous tests and research to ensure the safety of these drugs, especially for diabetics with heart problems.
He pointed out that some drugs that appeared previously to treat diabetes were causing the deterioration of the heart condition, and sometimes leading to the prolapse of the heart muscle, so they were withdrawn from the market.
He continued: In 2008, the Food and Drug Administration withdrew the famous drug “Avandia” from the market, as it was extremely dangerous for heart patients.
He added that the latest group of drugs that treat diabetes is the group that helps excrete additional amounts of sugar into the blood through urine.
He emphasized that the drug is a revolution in the treatment of diabetes, and one of its most important features is that it does not cause a sudden drop in the level of sugar in the blood, which makes it more effective compared to other diabetes medicines, but the use of this type of medicine requires the safety of the kidneys, as it does not work in a way. Good in cases of kidney failure.Dr. Mary Nabil, Professor of Diabetes and Endocrinology at the Faculty of Medicine, Qasr Al-Ainy, confirmed to the patients that the new drug is of great importance, in light of the Corona pandemic, as it reduces the possibility of it being exposed to heart health problems that require admission to hospitals.
And she continued: Diabetics is one of the most dangerous groups when infected with Corona, so all precautionary measures must be followed and avoid frequenting health facilities.
She pointed out that most of the complications of diabetes are in the heart and kidneys, and the patient may not feel them
Dr. Yasser Baghdadi, Professor of Cardiology at the Faculty of Medicine, Qasr Al-Aini, said that myocardial prolapse patients often visit hospitals, explaining that the American Heart Association revealed in its last conference that the new drug reduces death due to heart attacks by 32% and hospitalization by 35% 5
Dr. George Maher, General Manager of Eva Pharma, said that the company launched Melitofex, and made it available in the market less than a year ago, and it is a drug that has proven effective in treating diabetics who have problems with the pancreas, as it works by “the kidneys.”
In the same context, Dr. George Maher, General Manager of Eva Pharma, said that the company launched Melitofex, and made it available in the market less than a year ago, at 40% of the price of the imported medicine, and it has proven effective in treating diabetics who have problems with the pancreas. It works by “the kidneys.”
He pointed out that the drug is available in more than one focus so that the treating doctor has several alternatives that he chooses most suitable for the patient who is pursuing his treatment, and stressed that his company is intensifying its efforts in the field of scientific research, and providing everything new to diabetics and all patients.